| Opioids |
1 |
1 |
| Pain Management |
0 |
1 |
| Pain |
0 |
0.69 |
| Rheumatic Disease |
0 |
0.4 |
| Psoriatic Arthritis |
0 |
0.36 |
| Nonsteroidal Anti-Inflammatory Agents |
0 |
0.35 |
| Arthritis |
0 |
0.3 |
| Rheumatoid Arthritis |
0 |
0.25 |
| Spondylitis, Spondylosis, Kyphosis |
0 |
0.24 |
| Anticonvulsant |
0 |
0.2 |
| Systemic Sclerosis |
0 |
0.2 |
| Skeletal Myoblasts |
0 |
0.18 |
| Epilepsy |
0 |
0.15 |
| Scleroderma |
0 |
0.15 |
| Neuromuscular Blocking Agents |
0 |
0.14 |
| Systemic Lupus Erythematosus |
0 |
0.13 |
| Analgesia |
0 |
0.1 |
| Ankylosing Spondylitis |
0 |
0.1 |
| Antidepressant drug |
0 |
0.1 |
| Artificial Intelligence |
0 |
0.1 |
| California |
0 |
0.1 |
| Disability |
0 |
0.1 |
| Grant |
0 |
0.1 |
| Lupus |
0 |
0.1 |
| Muscle |
0 |
0.1 |
| Physical Therapy |
0 |
0.1 |
| Quality of Life |
0 |
0.1 |
| Skeletal |
0 |
0.1 |
| Axial spondyloarthritis |
0 |
0.07 |
| Depression |
0 |
0.07 |
| Healthcare and Medical Technology |
0 |
0.07 |
| Physical Medicine and Rehabilitation (PMR) |
0 |
0.07 |